Chapter 9. Artefill: the First to Last

  1. Derek Jones Director Founder Clinical Associate Professor
  1. Adam M. Rotunda MD Assistant Clinical Professor1 and
  2. Rhoda S. Narins MD Director Clinical Professor2

Published Online: 10 MAR 2010

DOI: 10.1002/9781444315004.ch9

Injectable Fillers: Principles and Practice

Injectable Fillers: Principles and Practice

How to Cite

Rotunda, A. M. and Narins, R. S. (2010) Artefill: the First to Last, in Injectable Fillers: Principles and Practice (ed D. Jones), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444315004.ch9

Editor Information

  1. David Geffin School of Medicine, University of California, Los Angeles, USA

Author Information

  1. 1

    Division of Dermatology (Medicine) David Geffen School of Medicine, University of California, Los Angeles, USA

  2. 2

    Division of Dermatology Surgery and Laser Center, Dermatology, New York University School of Medicine, New York, USA

Publication History

  1. Published Online: 10 MAR 2010
  2. Published Print: 31 MAR 2010

ISBN Information

Print ISBN: 9781405192897

Online ISBN: 9781444315004

SEARCH

Keywords:

  • Artefill;
  • polymethylmethacrylate PMMA;
  • permanent filler;
  • injectable filler;
  • nonresorbable filler;
  • nasolabial folds;
  • facial augmentation

Summary

Conventional approaches to facial folds are surgical augmentation or minimally invasive injectables, which until recently, have been limited to resorbable fillers. Artefill is currently the only soft-tissue filler cleared by the FDA in 2006 to address the unmet need for a non-resorbable filler indicated for the correction of nasolabial folds. Artefill is composed of polymethylmethacrylate (PMMA) microspheres suspended in bovine collagen containing lidocaine. The unique durability of the product presents safety concerns that are not germane to conventional, non-permanent products. This chapter describes Artefill's history and evolution, pivotal trial efficacy and safety data, and its uses and limitations in clinical practice